Concepedia

Author

Richard Grove

GlaxoSmithKline (United Kingdom)

Also Known As

Grove, Richard, R. A. Grove, Richard A. Grove, Richard Grove

33

Publications

1.2K

Citations

12

H-Index

19

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)GlaxoSmithKline (United States)ViiV Healthcare (United Kingdom)Research Triangle Park FoundationJanssen (Belgium)
RG

About

Richard Grove is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, neuroimmunology, and neurology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

170

2

Neurology

2

2

104

3

Health Sciences

1

1

27

4

Social Sciences

1

1

66

5

Immunology

1

1

27

Richard Grove

×

14

Publications

1.1K

Citations

12

H-Index

YearCitations

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis

Per Soelberg Sørensen, Steen Lisby, Richard Grove,

Neurology

2014

270

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

Amit Bar‐Or, Richard Grove, Daren Austin,

Neurology

2018

208

Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis

K. Hewett, Donald B. Sanders, Richard Grove,

Neurology

2018

123

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study

Caryl Schwartzbach, Richard Grove, Robert A. Brown,

Journal of Neurology

2016

109

A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease

Richard Grove, Conn Harrington, Andreas Mahler,

Current Alzheimer Research

2014

108

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial

David H. Miller, Thomas Weber, Richard Grove,

The Lancet Neurology

2012

77

A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

L. Fredrik Jarskog, Martin T. Lowy, Richard Grove,

Schizophrenia Research

2015

66

Automated identification of brain new lesions in multiple sclerosis using subtraction images

Marco Battaglini, Francesca Rossi, Richard Grove,

Journal of Magnetic Resonance Imaging

2013

54

The MIRROR Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) (S23.006)

Amit Bar‐Or, Richard Grove, Daren Austin,

Neurology

2014

27

Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials

Emilie R Elliot, Joseph W. Polli, Parul Patel,

The Journal of Infectious Diseases

2023

15

Page 1